Marvel Biosciences Corp. focuses on developing synthetic chemical derivatives of approved drugs for new disease indications in Canada. The company faces significant concerns, including a low current ratio of 0.18, indicating liquidity issues, and a negative return on assets of -51.4%, suggesting inefficiencies in asset utilization. With a market cap of $8.47M and a stock price of $0.12, the valuation appears low, which may reflect investor skepticism about its growth prospects and financial health. Overall, while the biotechnology sector holds potential, Marvel's financial metrics raise red flags.
Loading financial metrics...
Company has $389K in cash but burned $290K last quarter. At this burn rate, only 1.3 quarters of runway remain without additional financing.
Company posted a loss of $-1.6M over the last year, representing Infinity% of revenue.
Debt of $1.7M is 4.4x the company's cash position of $389K.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.2M over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (April 30, 2025)